Clinical trials: Glucose Variability
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT00961324
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents with type 1 diabetes.
- Trial name
- NCT01497574
- Testing
- insulin detemir, insulin glargine
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
To evaluate the efficacy of empagliflozin administered orally once daily in postprandial glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as mono-therapy in Japanese patients with type 2 diabetes…
- Trial name
- NCT01947855
- Testing
- Empagliflozin
- Where
- 2 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients.
- Trial name
- VARIABLE (NCT01910441)
- Testing
- Vildagliptin, Glimepiride, Metformin
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes, Type 2 Diabetes
Closed Loop Glucose Control in a Simulated ICU Setting
This is a proof of concept safety study of a rule-based closed loop glucose control system designed for use in the intensive care unit setting.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Stress Induced Hyperglycemia
- Trial name
- NCT07646067
- Testing
- FUSION closed loop glucose control system
- Volunteers
- 6 people
- Sponsor
- Ideal Medical Technologies
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)
The objective of this study is to evaluate the efficacy on glycemic variability and safety of gemigliptin 50 mg orally administered once daily for 12 weeks compared with Dapagliflozin 10mg in patients with type 2 diabetes…
- Trial name
- NCT03202563
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg, Diet/exercise questionnaire
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- LG Chem
Diabetes Mellitus, Type 2
Diabetes-Specific Formula on Long Term Glycemic Control
The study aims to investigate the effect of a diabetes-specific formula (DSF) used as a (partial) meal replacement on long-term glycemic control and short-term glycemic variability in individuals with type 2 diabetes.
- Trial name
- NCT04345497
- Testing
- Diabetes-Specific Formula, Standard Of Care
- Where
- 5 sites in Malaysia, Thailand
- Volunteers
- 251 people
- Sponsor
- Abbott Nutrition
Type 2 Diabetes Mellitus
Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes
The purpose of this study is to compare the kinetics and biodynamics of inhaled Technosphere Insulin with those of subcutaneous (SC) regular human insulin.
- Trial name
- NCT00511719
- Testing
- Technosphere Insulin, Actrapid
- Volunteers
- 13 people
- Sponsor
- Mannkind Corporation
Diabetes, Diabetes Mellitus, Type 1
A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics
This trial is conducted in Europe. The aim is to compare changes in blood sugar and the number of periods where carbohydrate supplementation is needed to treat low blood sugar, during two different treatments with NN1250 (insulin…
- Trial name
- NCT00964964
- Testing
- insulin degludec
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
Primary Objective: To demonstrate the non-inferiority of insulin glargine 300 units per milliliter (U/ml) in comparison to insulin degludec 100 U/ml on glycemic control and variability in participants with diabetes mellitus.
- Trial name
- inRange (NCT04075513)
- Testing
- Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
- Where
- 7 sites in United States, Brazil and 5 more
- Volunteers
- 343 people
- Sponsor
- Sanofi
Diabetes, Healthy
Within-subject Variability of Insulin Detemir in Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to compare the within-subject variability of insulin detemir to that of another basal insulin analogue, insulin glargine in healthy volunteers.
- Trial name
- NCT01497535
- Testing
- insulin detemir, insulin glargine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Critically Ill Mechanically Ventilated Subjects
The DIVINE Study: DIetary Management of Glucose VarIability iN thE ICU
To compare the nutritional effect on blood glucose of two commercially available enteral diets in overweight or obese patients in the Intensive Care Unit.
- Trial name
- NCT02337556
- Testing
- Peptamen Bariatric, Replete
- Where
- 7 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Société des Produits Nestlé (SPN)
Type 2 Diabetes Mellitus
Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)
This is a randomized, double-blind, active control, parallel group, exploratory phase 4 study to compare the effect of teneligliptin versus sitagliptin on glucose variability when added on to metformin in patients with…
- Trial name
- NCT02512523
- Testing
- Teneligliptin, Sitagliptin
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Handok Inc.
Type 2 Diabetes Mellitus
Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
The purpose of the study is to assess if the addition of vildagliptin as add-on therapy improves glucose variability in type 2 diabetes mellitus (T2DM) patients inadequately controlled with insulin, with special emphasis in…
- Trial name
- VIDA (NCT01862263)
- Testing
- Vildagliptin, Insulin
- Where
- 13 sites in Mexico
- Volunteers
- 191 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus (T2DM)
Glycemic Variability of Combination Therapies in T2DM
Glycemic Variability of Combination Therapies in T2DM
- Trial name
- NCT07442006
- Testing
- Empagliflozin/Metformin, Anagliptin, Metformin
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- JW Pharmaceutical
Healthy, Impaired Glucose Tolerance
Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability
The purpose of this study is to determine the short-term effect of a nutritional program consisting of a yerba mate supplement, fiber supplement, and intermittent fasting on glycemic variability in men and women with risk factors…
- Trial name
- NCT05493553
- Testing
- Dietary supplement regimen, Dietary supplement and intermittent fasting regimen
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Unicity International, Inc.
Diabetes Mellitus, Type 2
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient…
- Trial name
- COMETA (NCT03267576)
- Testing
- Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin
- Where
- 5 sites in Mexico
- Volunteers
- 64 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Heart Failure, Type 2 Diabetes
Prognostic Impact of Diabetes and Weight Variability in Telemonitored Heart Failure
This observational cohort study evaluates the prognostic impact of diabetes, comorbidity burden, and short-term weight variability among adults with chronic heart failure enrolled in a nationwide remote patient monitoring program…
- Conditions
- Chronic Heart Failure, Type 2 Diabetes, Diabetes (DM)
- Trial name
- DM-HF-Tele (NCT07561866)
- Testing
- Diabetes Status, Comorbidity Burden, Weight variability
- Where
- France
- Volunteers
- 16,556 people
- Sponsor
- Satelia
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes Mellitus
Primary objective: To evaluate in explorative manner the fasting blood glucose (FBG) coefficient of variability (CV)calculated on SMBG values (SMBG : Self-Monitoring of Blood Glucose).
- Trial name
- NCT00272077
- Testing
- Insuline glargine
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional
This is a multi-center, prospective, non-pivotal, single arm, non-significant risk evaluation the Abbott Sensor Based Glucose Monitoring System - Pro across different stages of T2 diabetes management.
- Trial name
- NCT02336945
- Testing
- Abbott Sensor Based Glucose Monitoring System-Professional
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Abbott Diabetes Care